Form 4: Artiva Biotherapeutics SVP Tax Withholding

Artiva Biotherapeutics' SVP of Research and Development, Heather Raymon, reported a disposition of 1,375 common shares for tax obligations related to RSU vesting.

Summary

• Heather Raymon, SVP, Research and Development at Artiva Biotherapeutics, Inc. (ARTV), reported a transaction.
• On November 15, 2025, 1,375 shares of common stock were disposed of.
• These shares were withheld by the company to cover income tax obligations arising from the vesting of restricted stock unit awards.
• The price per share for the disposition was $3.25.
• Following this transaction, Ms. Raymon beneficially owns 39,591 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary tax withholding related to RSU vesting, which is neutral in terms of company performance or outlook.

Positives

• The transaction is a routine tax withholding, indicating the vesting of restricted stock units, which can be seen as a positive for employee retention and compensation structure.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries for publicly traded companies when restricted stock units vest. It does not reflect a discretionary sale or purchase based on market views.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes related to executive compensation.
• Employees holding similar RSU awards would view this as a standard part of their compensation structure.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary tax withholding event for an executive's restricted stock units. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for buying or selling.

Keywords

Artiva Biotherapeutics, ARTV, Form 4, Insider Transaction, Stock Vesting, Tax Withholding, Restricted Stock Units, Heather Raymon, SVP Research and Development